Compounded tirzepatide
Sold by Lumora MD · every compounded tirzepatide record
The register has not established whether this program ships a vial, a pen, or another form. That is a gap in our record, not a statement about the company.
Recorded initial charges
First month
$325
first month, including required fees on record. The published monthly rate excludes one-time and annual fees; introductory and conditional rates may change. Some fee details are unverified or unpublished; this sum does not establish the full amount payable.
| Medication · Tirzepatide + Glycine, standard (subcutaneous injectable, weekly) · recorded initial monthly payment | $325 |
|---|
Added from the figures recorded below.
Price
| Term | Per month | Charged today |
|---|---|---|
| Tirzepatide + Glycine, standard (subcutaneous injectable, weekly) “Tirzepatide + Glycine $325 through secure checkout” | Per month$325 | Charged today$325 |
Price sources
- Tirzepatide + Glycine, standard (subcutaneous injectable, weekly) · lumoramd.com — read September 2026
We earn nothing from this link. It opens Lumora MD's website without a paid referral.
History
Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.
- September 2026 — Entry added to the register
Sourcing and terms
| States | Not disclosed as of September 2026 |
|---|---|
| Prescriber | Asynchronous review |
| Cancellation | Subscriptions renew automatically until cancelled. Cancel at any time through your account settings or by contacting support@lumoramd.com before your next billing date. |
Not yet checked: pharmacy, membership and consult fee.
Recorded from lumoramd.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Notes
- 1. September 2026 — Text fetcher found nothing at /pricing, /weight-loss, /semaglutide (all 404); the real catalog lives under /medications/. This is the richest recovery in the batch: separate priced product pages for semaglutide and tirzepatide in sublingual/oral-drop form (1, 2, and 3-month supply tiers) AND separate subcutaneous-injectable variants combined with B12 or glycine (5 dose tiers for semaglutide, 6 for tirzepatide, each with its own price, not fully enumerated here). Both drugs are explicitly called 'compounded' ('This formulation combines compounded semaglutide...'). The injectable variants are described only as 'subcutaneous injectable' — never 'vial' — so form is left not-disclosed for those; the drops variants are explicitly 'Sublingual/Oral Drops'.
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.